Clinical similarity, economic divergence: cost-effectiveness and population health implications of dietary, pharmacological, and exercise interventions in older adults with type 2 diabetes: a secondary analysis of a randomized controlled trial. (PubMed, BMC Geriatr) - Oct 22, 2026 - P4 | "We conducted a secondary analysis of the CEV-65 randomized controlled trial (n = 100 older adults aged 65 years and older with type 2 diabetes), comparing a Mediterranean diet (VegMedD), pharmacological treatment (empagliflozin), and exercise (circuit resistance training)...These findings should be interpreted as exploratory and should not be extrapolated to long-term comparative effectiveness, particularly given the established long-term cardiovascular and renal benefits of SGLT2 inhibitors that could not be captured within the 10-week follow-up period. ClinicalTrials.gov (Identifier: NCT03560375; registered on June 5, 2018) https://clinicaltrials.gov/study/NCT03560375?tab=history ."
Clinical • HEOR • Journal • Cardiovascular • Diabetes • Metabolic Disorders • Preventive care • Type 2 Diabetes Mellitus
|
|
Assaf Buch; Iris Yaish; Limor Dina Gonen; Roy Eldor; Sharon Barak
|